Research Article
CD44, Sonic Hedgehog, and Gli1 Expression Are Prognostic Biomarkers in Gastric Cancer Patients after Radical Resection
Table 1
Clinicopathological characteristics of CD44, Shh, and Gli1 in gastric cancer after radical resection.
| | Factors | Cases | CD44 | Shh | GLI1 | | Positive () | Negative () | value | Positive () | Negative () | value | Positive () | Negative () | value |
| | Age | | | | 0.089 | | | 0.777 | | | 0.936 | | <60 years | 51 | 34 (57.6%) | 17 (40.5%) | | 37 (51.4%) | 14 (48.3%) | | 31 (50.8%) | 20 (50.0%) | | | ≧60 years | 50 | 25 (42.4%) | 25 (59.5%) | | 35 (48.6%) | 15 (51.7%) | | 30 (49.2%) | 20 (50.0%) | | | Gender | | | | 0.460 | | | 0.929 | | | 0.852 | | Male | 62 | 38 (64.4%) | 24 (57.1%) | | 44 (61.1%) | 18 (62.1%) | | 37 (60.7%) | 25 (62.5%) | | | Female | 39 | 21 (35.6%) | 18 (42.9%) | | 28 (38.9%) | 11 (37.9%) | | 24 (39.3%) | 15 (37.5%) | | | Tumor location | | | | 0.684 | | | 0.891 | | | 0.440 | | Upper 1/3 | 21 | 13 (22.0%) | 8 (19.0%) | | 15 (20.8%) | 6 (20.7%) | | 13 (21.3%) | 8 (20.0%) | | | Middle 1/3 | 25 | 13 (22.0%) | 12 (28.6%) | | 19 (26.4%) | 6 (20.7%) | | 12 (19.7%) | 13 (32.5%) | | | Lower 1/3 | 50 | 29 (49.2%) | 21 (50.0%) | | 35 (48.6%) | 15 (51.7%) | | 32 (52.5%) | 18 (45.0%) | | | Whole | 5 | 4 (6.8%) | 1 (2.4%) | | 3 (4.2%) | 2 (6.9%) | | 4 (6.6%) | 1 (2.5%) | | | Tumor size | | | | 0.038 | | | <0.001 | | | <0.001 | | <5 cm | 34 | 15 (25.4%) | 19 (45.2%) | | 16 (22.2%) | 18 (62.1%) | | 11 (18.0%) | 23 (57.5%) | | | ≥5 cm | 67 | 44 (74.6%) | 23 (54.8%) | | 56 (77.8%) | 11 (37.9%) | | 50 (82.0%) | 17 (42.5%) | | | Histological type | | | | 0.004 | | | 0.002 | | | 0.002 | | Differentiated | 30 | 11 (18.6%) | 19 (45.2%) | | 15 (20.8%) | 15 (51.7%) | | 11 (18.0%) | 19 (47.5%) | | | Undifferentiated | 71 | 48 (81.4%) | 23 (54.8%) | | 57 (79.2%) | 14 (48.3%) | | 50 (82.0%) | 21 (52.5%) | | | Gross type | | | | 0.501 | | | <0.001 | | | <0.001 | | Noninfiltration | 30 | 16 (27.1%) | 14 (33.3%) | | 13 (18.1%) | 17 (58.6%) | | 10 (16.4%) | 20 (50.0%) | | | Infiltration | 71 | 43 (72.9%) | 28 (66.7%) | | 59 (81.9%) | 12 (41.1%) | | 51 (83.6%) | 20 (50.0%) | | | T stage (7th) | | | | <0.001 | | | <0.001 | | | <0.001 | | I | 10 | 2 (3.4%) | 8 (19.0%) | | 3 (4.2%) | 7 (24.1%) | | 2 (3.3%) | 8 (20.0%) | | | II | 21 | 7 (11.9%) | 14 (33.3%) | | 7 (9.7%) | 14 (48.3%) | | 3 (4.9%) | 18 (45.0%) | | | III | 20 | 10 (16.9%) | 10 (23.8%) | | 13 (18.1%) | 7 (24.1%) | | 10 (16.4%) | 10 (25.0%) | | | IVa | 30 | 23 (39.0%) | 7 (16.7%) | | 29 (40.3%) | 1 (3.4%) | | 26 (42.6%) | 4 (10.0%) | | | IVb | 20 | 17 (28.8%) | 3 (7.1%) | | 20 (27.8%) | 0 (0.0%) | | 20 (32.8%) | 0 (0.0%) | | | N stage (7th) | | | | 0.005 | | | 0.010 | | | <0.001 | | N0 | 39 | 15 (25.4%) | 24 (57.1%) | | 21 (29.2%) | 18 (62.1%) | | 14 (23.0%) | 25 (62.5%) | | | N1 | 16 | 9 (15.3%) | 7 (16.7%) | | 11 (15.3%) | 5 (17.2%) | | 11 (18.0%) | 5 (12.5%) | | | N2 | 24 | 17 (28.8%) | 7 (16.7%) | | 21 (29.2%) | 3 (10.3%) | | 16 (26.2%) | 8 (20.0%) | | | N3 | 22 | 18 (30.5%) | 4 (9.5%) | | 19 (26.4%) | 3 (10.3%) | | 20 (32.8%) | 2 (5.0%) | | | TNM stage (7th) | | | | <0.001 | | | <0.001 | | | <0.001 | | I | 22 | 4 (6.8%) | 18 (42.9%) | | 5 (6.9%) | 17 (58.6%) | | 2 (3.3%) | 20 (50.0%) | | | II | 21 | 10 (16.9%) | 11 (26.2%) | | 15 (20.8%) | 6 (20.7%) | | 9 (14.8%) | 12 (30.0%) | | | III | 33 | 45 (76.3%) | 13 (31.0%) | | 52 (72.2%) | 6 (20.7%) | | 50 (82.0%) | 8 (20.0%) | |
|
|
